A Phase 1 Study of BMF-500 in Adults With Acute Leukemia
type: MedicalStudy
description: A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of BMF-500, an Oral Covalent FLT3 Inhibitor, in Adults With Acute Leukemia
status: ACTIVE_NOT_RECRUITING
study design: INTERVENTIONAL
phase: PHASE1
start date: 2023-07-26
end date: 2026-04
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT05918692
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Biomea Fusion Inc.
study subject: Acute Myeloid Leukemia
keywords: PHASE1
keywords: INTERVENTIONAL
keywords: ACTIVE_NOT_RECRUITING
keywords: Acute Myeloid Leukemia

AI Analytics
type: Organization